Authors
Loading...
Preclinical apoM findings warrant human validation; leaves open therapeutic targeting of S1P carriers in metabolic disease.
Key points are not available for this paper at this time.
Christoffersen et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: